ID   SU-DHL-8
AC   CVCL_2207
SY   SUDHL8; SUDHL-8; SuDHL 8; Stanford University-Diffuse Histiocytic Lymphoma-8; DHL-8; DHL8
DR   CLO; CLO_0037064
DR   EFO; EFO_0006493
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-2961
DR   BioGRID_ORCS_Cell_line; 1026
DR   BioSample; SAMN03471060
DR   BioSample; SAMN10988104
DR   cancercelllines; CVCL_2207
DR   Cell_Model_Passport; SIDM00423
DR   ChEMBL-Cells; CHEMBL4523531
DR   ChEMBL-Targets; CHEMBL4523562
DR   Cosmic; 1067442
DR   Cosmic; 1079256
DR   Cosmic; 1295511
DR   Cosmic; 1517639
DR   Cosmic; 1541913
DR   Cosmic; 1636689
DR   Cosmic; 2276342
DR   Cosmic; 2361381
DR   Cosmic; 2437316
DR   Cosmic-CLP; 1331038
DR   DepMap; ACH-000656
DR   DSMZ; ACC-573
DR   DSMZCellDive; ACC-573
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   EGA; EGAS00001002554
DR   GDSC; 1331038
DR   GEO; GSM380149
DR   GEO; GSM552467
DR   GEO; GSM887656
DR   GEO; GSM888748
DR   GEO; GSM1035316
DR   GEO; GSM1374909
DR   GEO; GSM1670488
DR   IARC_TP53; 28301
DR   LiGeA; CCLE_179
DR   LINCS_LDP; LCL-1139
DR   PharmacoDB; SUDHL8_1505_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_2207
DR   PubChem_Cell_line; CVCL_2207
DR   Wikidata; Q54970731
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=83902;
RX   PubMed=177185;
RX   PubMed=214220;
RX   PubMed=371794;
RX   PubMed=3881165;
RX   PubMed=8547074;
RX   PubMed=19278952;
RX   PubMed=20628145;
RX   PubMed=22460905;
RX   PubMed=25355872;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Doubling time: ~48-72 hours (DSMZ=ACC-573).
CC   HLA typing: A*03:01,03:01; B*44:02,44:02; C*05:01,05:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Pro648Thrfs*2 (c.1940dupC) (c.1940_1941insC); ClinVar=VCV000432829; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234Asn (c.700T>A); ClinVar=VCV000376692; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Gly (c.745A>G); ClinVar=VCV000376654; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Omics: Virome analysis using RNAseq.
CC   Genome ancestry: African=0.67%; Native American=0%; East Asian, North=0.1%; East Asian, South=0%; South Asian=2.54%; European, North=64.1%; European, South=32.58% (PubMed=30894373).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): ATCC; Cosmic-CLP; DSMZ; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11,13
ST   D16S539: 12
ST   D18S51: 14,19
ST   D19S433: 13
ST   D21S11: 30,31.2
ST   D2S1338: 17,20
ST   D3S1358: 14,15
ST   D5S818: 11,13
ST   D7S820: 8
ST   D8S1179: 13 (PubMed=25877200)
ST   D8S1179: 13,18 (DSMZ)
ST   FGA: 25
ST   Penta D: 11,12
ST   Penta E: 14,17
ST   TH01: 6,9
ST   TPOX: 8
ST   vWA: 15,19
DI   NCIt; C36080; Diffuse large B-cell lymphoma germinal center B-cell type
DI   ORDO; Orphanet_544; Diffuse large B-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   59Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 41
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=83902; DOI=10.1002/1097-0142(197901)43:1<1::AID-CNCR2820430102>3.0.CO;2-M;
RA   Kaplan H.S., Goodenow R.S., Gartner S., Bieber M.M.;
RT   "Biology and virology of the human malignant lymphomas: 1st Milford D.
RT   Schulz Lecture.";
RL   Cancer 43:1-24(1979).
//
RX   PubMed=177185; DOI=10.1002/1097-0142(197605)37:5<2158::AID-CNCR2820370503>3.0.CO;2-F;
RA   Epstein A.L., Herman M.M., Kim H., Dorfman R.F., Kaplan H.S.;
RT   "Biology of the human malignant lymphomas. III. Intracranial
RT   heterotransplantation in the nude, athymic mouse.";
RL   Cancer 37:2158-2176(1976).
//
RX   PubMed=214220; DOI=10.1002/1097-0142(197811)42:5<2379::AID-CNCR2820420539>3.0.CO;2-4;
RA   Epstein A.L., Levy R., Kim H., Henle W., Henle G., Kaplan H.S.;
RT   "Biology of the human malignant lymphomas. IV. Functional
RT   characterization of ten diffuse histiocytic lymphoma cell lines.";
RL   Cancer 42:2379-2391(1978).
//
RX   PubMed=371794;
RA   Epstein A.L., Kaplan H.S.;
RT   "Feeder layer and nutritional requirements for the establishment and
RT   cloning of human malignant lymphoma cell lines.";
RL   Cancer Res. 39:1748-1759(1979).
//
RX   PubMed=3881165; DOI=10.1016/0165-4608(85)90186-4;
RA   Kaiser-McCaw Hecht B., Epstein A.L., Berger C.S., Kaplan H.S.,
RA   Hecht F.;
RT   "Histiocytic lymphoma cell lines: immunologic and cytogenetic
RT   studies.";
RL   Cancer Genet. Cytogenet. 14:205-218(1985).
//
RX   PubMed=8547074; DOI=10.1111/j.1365-2141.1995.tb05302.x;
RA   Siebert R., Willers C.P., Schramm A., Fossa A., Dresen I.M.G.,
RA   Uppenkamp M., Nowrousian M.R., Seeber S., Opalka B.;
RT   "Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and
RT   lymphoblastic leukaemia cell lines.";
RL   Br. J. Haematol. 91:350-354(1995).
//
RX   PubMed=19278952; DOI=10.1182/blood-2009-01-202028;
RA   Li C., Kim S.-W., Rai D., Bolla A.R., Adhvaryu S., Kinney M.C.,
RA   Robetorye R.S., Aguiar R.C.T.;
RT   "Copy number abnormalities, MYC activity, and the genetic fingerprint
RT   of normal B cells mechanistically define the microRNA profile of
RT   diffuse large B-cell lymphoma.";
RL   Blood 113:6681-6690(2009).
//
RX   PubMed=20628145; DOI=10.1182/blood-2010-05-282780;
RA   Green M.R., Monti S., Rodig S.J., Juszczynski P., Currie T.,
RA   O'Donnell E., Chapuy B., Takeyama K., Neuberg D., Golub T.R.,
RA   Kutok J.L., Shipp M.A.;
RT   "Integrative analysis reveals selective 9p24.1 amplification,
RT   increased PD-1 ligand expression, and further induction via JAK2 in
RT   nodular sclerosing Hodgkin lymphoma and primary mediastinal large
RT   B-cell lymphoma.";
RL   Blood 116:3268-3277(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25355872; DOI=10.1128/JVI.02570-14;
RA   Cao S.-B., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z.,
RA   O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.;
RT   "High-throughput RNA sequencing-based virome analysis of 50 lymphoma
RT   cell lines from the Cancer Cell Line Encyclopedia project.";
RL   J. Virol. 89:713-729(2015).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//